By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: How Many Melanoma Patients Did the FDA Kill?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > How Many Melanoma Patients Did the FDA Kill?
BusinessPublic Health

How Many Melanoma Patients Did the FDA Kill?

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

By my estimate, more than 1,000 people have died prematurely because of foot-dragging by the FDA. Here’s why. After an “expedited” analysis that lasted a year and a half, the FDA has finally approved Bristol-Myers Squibbs’ Yervoy (ipilimunab) for metastatic melanoma. The deadliest type of skin cancer, melanoma killed 8,700 Americans last year, according to the National Cancer Institute. BMS submitted its application to the FDA on August 18, 2010, with a target date for approval of December 25. On November 2, the FDA pushed out the target date. On March 25, the FDA approved the lifesaving medicine. So, the question is: How many patients did the FDA kill by delaying the medicine? Well, 46 percent of the subjects taking the drug were alive one year later, and 20 percent were alive two years later. In the control group, only 25 percent survived one year, and 14 percent two years. The difference between 46 percent and 25 percent is 21 percent. 21 percent of 8,700 is 1,827 lives. Similarly, the difference between 20 percent and 14 percent is 6 percent, or 522 of 1,827 lives. Assuming that BMS was willing to supply the medicine as of August 18, 2010, the FDA’s initial period of review (to December 25) took 129 days. This implies that 645 melanoma patients died a year earlier than they would have without the legal requirement for FDA approval. However, because the FDA delayed a further 90 days (to March 25), 450 more patients died a year early. The point estimate for the total number of melanoma patients who died a year early is 1,095. Of course, many of those would have died after another year. The delay only cost 313 patients two years of life. But I hardly think that’s a comfort to melanoma victims and their families.

TAGGED:FDApublic health
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025
pool chemicals harming health
Beyond The Splash: How Pool Chemicals Can Harm Respiratory Health
Infographics
September 28, 2025
How AI Is Reshaping Medical Manufacturing
How AI Is Reshaping Medical Manufacturing
Global Healthcare Technology
September 28, 2025
doctor looking at his wristwatch
When Mistakes Happen in Hospitals and Lives Are at Stake
Hospital Administration
September 26, 2025

You Might also Like

BusinessTechnology

Diabetes management trends

May 26, 2011

Finally: An FDA (Draft) Guidance for Social Media in Medical Marketing

January 21, 2014

Drug Dispensing Robot at Hospital Pharmacy

March 13, 2011

What Is on the Digital Horizon for Clinical Trial Recruitment?

February 3, 2015
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?